Cefovecin

Jump to: navigation, search
Cefovecin
Cefovecin Wiki Str.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • do not administer to pregnant cat or during breeding or lactation period.
Routes of
administration
dorsoscapular subcutaneous injection
ATCvet code
Legal status
Legal status
  • Veterinary use only
Pharmacokinetic data
Protein bindingDogs: 98.5%, Cats: 99.8%
Metabolismnone
Elimination half-lifeDogs: 133 hours, Cats: 166 hours
Excretionunchanged in urine/bile
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC17H19N5O6S2
Molar mass453.49 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Cefovecin

Articles

Most recent articles on Cefovecin

Most cited articles on Cefovecin

Review articles on Cefovecin

Articles on Cefovecin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cefovecin

Images of Cefovecin

Photos of Cefovecin

Podcasts & MP3s on Cefovecin

Videos on Cefovecin

Evidence Based Medicine

Cochrane Collaboration on Cefovecin

Bandolier on Cefovecin

TRIP on Cefovecin

Clinical Trials

Ongoing Trials on Cefovecin at Clinical Trials.gov

Trial results on Cefovecin

Clinical Trials on Cefovecin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cefovecin

NICE Guidance on Cefovecin

NHS PRODIGY Guidance

FDA on Cefovecin

CDC on Cefovecin

Books

Books on Cefovecin

News

Cefovecin in the news

Be alerted to news on Cefovecin

News trends on Cefovecin

Commentary

Blogs on Cefovecin

Definitions

Definitions of Cefovecin

Patient Resources / Community

Patient resources on Cefovecin

Discussion groups on Cefovecin

Patient Handouts on Cefovecin

Directions to Hospitals Treating Cefovecin

Risk calculators and risk factors for Cefovecin

Healthcare Provider Resources

Symptoms of Cefovecin

Causes & Risk Factors for Cefovecin

Diagnostic studies for Cefovecin

Treatment of Cefovecin

Continuing Medical Education (CME)

CME Programs on Cefovecin

International

Cefovecin en Espanol

Cefovecin en Francais

Business

Cefovecin in the Marketplace

Patents on Cefovecin

Experimental / Informatics

List of terms related to Cefovecin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cefovecin (INN) is an antibiotic of the cephalosporin class, licensed for the treatment of skin infections in cats and dogs. It is marketed by Zoetis under the trade name Convenia. It is the first single-dose injectable antibiotic for dogs and cats that assures owner compliance with dosing for the animal. It is used for the treatment of skin infections caused by Pasturella multocida in cats, and Streptococcus intermedius/S. canis in dogs. The advantage of using injectable antibiotics is not missing a dose that can allow partially resistant microbes to recover during missed doses. It is highly effective, but should not be used in pregnant or lactating animals or in animals with a history of allergies to penicillin or cephalosporin drugs.[1]

Approval and usage

Cefovecin was first authorized for use in the European Union in June 2006,[2] and was approved for use in the United States in June 2008.[3]

It is approved as a broad-spectrum, fourth-generation cephalosporin for subcutaneous injection lasting 14 days for treating skin and soft tissue infections.[4]

Precautions

Contraindications include known allergies to cefovecin or antibiotics containing β-lactam rings such as penicillin or cephalosporins. Adverse reactions can include anaphylaxis. It is not for use in humans and should be kept out of reach of children. Individuals with similar known allergies should avoid dermal contact when handling the drugs.

Adverse reactions in dogs can include lethargy, decreased appetite, vomiting, diarrhea, blood in feces, and flatulence. Adverse reactions in cats can include vomiting, diarrhea, decreased appetite, lethargy, odd hyperactive behavior, and inappropriate urination. Mildly increased serum ALT and gamma glutamyl transferase have been noted.[5]

Effectiveness

Cefovecin functions by interfering with cell wall synthesis. The chemical covalently binds to the so-called penicillin-binding proteins. Due to the high protein-binding of the chemical, it is not effective against Pseudomonas spp., or enterococci.

In drug studies, cefovecin administered to dogs was 92.4% effective against skin infections (secondary superficial pyoderma, abscesses, and infected wounds). In cats, it was 96.8% effective against skin infections.[6]

References

  1. Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.
  2. "European Public Assessment Report for Convenia (from the EMEA website)". Retrieved 2008-07-11.
  3. "FDA Approves First and Only Single-dose Antibiotic for Dogs and Cats" (Press release). Pfizer Inc. 2008-06-30. Retrieved 2008-07-11.
  4. Pfizer Animal Health. "Convenia". Pfizer. Retrieved 29 January 2013.
  5. Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.
  6. Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.

External links


Linked-in.jpg